体外循环相关凝血病的管理
该综述指出体外循环(CPB)相关凝血病通常为多因素所致,很少仅因肝素逆转不充分。文章总结了术前药物管理、抗纤溶药物、血液回输等减少输血的辅助措施,以及床旁黏弹性与血小板功能检测在指导成分输血中的作用,并强调识别常见管理陷阱。
要点
- CPB相关凝血病多为多因素,不能仅归因于肝素逆转不足。
- 术前抗凝抗血小板药物管理是减少出血的关键环节。
- 床旁黏弹性与血小板功能检测有助于目标导向成分输血。
核心结论
- 有效管理CPB相关凝血病可显著改善患者结局。
研究设计与样本
- 综述,检索范围限于CPB相关凝血病管理。
主要发现
- CPB回路组件诱导全身炎症及凝血与纤溶系统多重紊乱。
- 脱离CPB时出血量增加与不良结局及死亡相关。
- 抗纤溶药、红细胞回收、 sequestration及逆行自体预充等减少输血的措施证据程度不一。
- 识别患者与操作危险因素有助于预判凝血病。
临床怎么用
- 术前管理抗凝及抗血小板药物以降低出血风险。
- 使用抗纤溶药及血液保护措施减少输血。
- 基于床旁黏弹性与血小板功能检测指导成分输血。
- 避免鱼精蛋白过量逆转肝素及忽视外科性出血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiopulmonary bypass (CPB) has allowed for significant surgical advancements, but accompanying risks can be significant and must be expertly managed. One of the foremost risks is coagulopathic bleeding. Increasing levels of bleeding in cardiac surgical patients at the time of separation from CPB are associated with poor outcomes and mortality. CPB-associated coagulopathy is typically multifactorial and rarely due to inadequate reversal of systemic heparin alone. The components of the bypass circuit induce systemic inflammation and multiple disturbances of the coagulation and fibrinolytic systems. Anticipating coagulopathy is the first step in managing it, and specific patient and procedural risk factors have been identified as predictors of excessive bleeding. Medication management pre-procedure is critical, as patients undergoing cardiac surgery are commonly on anticoagulants or antiplatelet agents. Important adjuncts to avoid transfusion include antifibrinolytics, and perfusion practices such as red cell salvage, sequestration, and retrograde autologous priming of the bypass circuit have varying degrees of evidence supporting their use. Understanding the patient's coagulation status helps target product replacement and avoid larger volume transfusion. There is increasing recognition of the role of point-of-care viscoelastic and functional platelet testing. Common pitfalls in the management of post-CPB coagulopathy include overdosing protamine for heparin reversal, imperfect laboratory measures of thrombin generation that result in normal or near-normal laboratory results in the presence of continued bleeding, and delayed recognition of surgical bleeding. While challenging, the effective management of CPB-associated coagulopathy can significantly improve patient outcomes.
引用
- Bartoszko J, Karkouti K. Managing the coagulopathy associated with cardiopulmonary bypass. J Thromb Haemost. 2020. PMID: 33251719. doi:10.1111/jth.15195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。